Understand the source comparison
Selank Amidate BDNF Elevation Research: Comparison
Selank Intranasal (primary) 15–32% hippocampal increase None published Indirect; likely stress-mediated Promising preclinical, unvalidated human translation SEMAX Intranasal 10–25% cortical increase Phase II cognitive trials (Russia) ACTH-derived; better chara
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selank
- Intranasal (primary)
- 15–32% hippocampal increase
- None published
- Indirect; likely stress-mediated
- Promising preclinical, unvalidated human translation
- SEMAX
- Intranasal
- 10–25% cortical increase
- Phase II cognitive trials (Russia)
- ACTH-derived; better characterised
- Stronger human evidence, similar mechanism gaps
- Cerebrolysin
- Intravenous
- 18–40% serum increase
- Multiple stroke recovery RCTs
- Direct receptor agonism
- Most robust human BDNF data available
- Dihexa
- Oral (experimental)
- 45–60% in vitro receptor activation
- Phase I safety only
- Direct TrkB receptor binding
- Strongest mechanism, no efficacy proof yet